Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: Int J Cancer. 2013 Jan 18;132(11):2502–2509. doi: 10.1002/ijc.27910

Figure 1.

Figure 1

Kaplan-Meier survival estimates between patients with duodenal adenocarcinomas with KRAS mutations and those with wild-type KRAS: (a) overall survival, (b) relapse-free survival. P values were based on the log-rank test.